Niacin, lipids, and heart disease

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Niacin is a potent medication for increasing high-density lipoprotein (HDL) cholesterol.
• It exhibits a broad impact on the lipid profile, reducing atherogenic apolipoprotein B and increasing antiatherogenic apolipoprotein AI.
• Niacin has demonstrated reductions in atherosclerotic complications and mortality in clinical trials.

Purpose of the Study:

• To elucidate novel molecular mechanisms of niacin's action in the liver.
• To explore the potential for niacin in new drug discovery and combination therapies.
• To evaluate the safety and efficacy of niacin, particularly in combination with statins, for patients with diabetes.

Main Methods:

• Investigated niacin's inhibitory effects on diacylglycerol acyltransferase 2 (DGAT2) in the liver.
• Examined niacin's impact on the HDL apo AI catabolism pathway.
• Reviewed clinical trial data on niacin's safety and efficacy, including its use with HMG CoA reductase inhibitors (statins).

Main Results:

• Niacin directly inhibits DGAT2, explaining its effects on triglycerides and apo B lipoproteins.
• Niacin inhibits the HDL apo AI catabolism pathway, leading to elevated HDL levels.
• Niacin is safe for patients with diabetes, and its combination with statins is both safe and effective.

Conclusions:

• Novel liver targets (DGAT2 and HDL apo AI catabolism) provide a mechanistic basis for niacin's lipid-modulating effects.
• Niacin's established safety profile, especially with statins in diabetic patients, supports its role in cardiovascular risk management.
• Further clinical trials are warranted to assess the benefits of niacin combined with other lipid-modulating agents on cardiovascular event reduction.